Comparison · NCT00841789-9dddc3fc
Arm 1 -Etanercept vs ARM 2 Placebo: IVIG Refractory
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 -Etanercept vs ARM 2 Placebo: IVIG Refractory. Trial comparisons, record NCT00841789-9dddc3fc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00841789-9dddc3fc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.13 | 0.0776 | 0.21 | wilson | |
| Risk in group 2 | 0.218 | 0.148 | 0.308 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0878 | -0.192 | 0.0179 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.597 | 0.319 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.537 | 0.253 | 1.14 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm 1 -Etanercept than on ARM 2 Placebo | 11.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 -Etanercept | Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin~Etanercept: etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis. | 13 | 100 | OG000 |
| Group 2 | ARM 2 Placebo | Placebo~Placebo: Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis. | 22 | 101 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- IVIG Refractory
- Description
The primary outcome is the proportion of subjects who become refractory to IVIG. Subjects requiring 1 dose of IVIG are classified as responders and subjects requiring more than 1 dose are classified as IVIG refractory.
- Time frame
- 42 days after initial dose
- Population
- All patients receiving study drug
Source ClinicalTrials.gov
Trial
- Title
- A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
- NCT number
- NCT00841789
- Phases
- PHASE2
- Conditions
- Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
- Interventions
- Etanercept, Placebo
- Lead sponsor
- Michael Portman
- Results first posted
- 2023-05-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00841789?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00841789-9dddc3fc